{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:47:28Z","timestamp":1790567248577,"version":"4.1.0"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1212\/con.0000000000000403","type":"journal-article","created":{"date-parts":[[2016,12,6]],"date-time":"2016-12-06T09:31:58Z","timestamp":1481016718000},"page":"1829-1851","source":"Crossref","is-referenced-by-count":43,"title":["Metabolic Myopathies"],"prefix":"10.1212","volume":"22","author":[{"given":"Mark A.","family":"Tarnopolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"5","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1152\/jappl.1993.75.5.2134","article-title":"Gender differences in leucine kinetics and nitrogen balance in endurance athletes","volume":"75","author":"Phillips SM","year":"1993","unstructured":"Phillips SM Atkinson SA Tarnopolsky MA MacDougall JD. Gender differences in leucine kinetics and nitrogen balance in endurance athletes. J Appl Physiol (1985) 1993;75(5):2134\u20132141.","journal-title":"J Appl Physiol (1985)"},{"issue":"4341","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.644316","article-title":"Myoadenylate deaminase deficiency: a new disease of muscle","volume":"200","author":"Fishbein WN","year":"1978","unstructured":"Fishbein WN Armbrustmacher VW Griffin JL. Myoadenylate deaminase deficiency: a new disease of muscle. Science 1978;200(4341):545\u2013548. doi:10.1126\/science.644316.","journal-title":"Science"},{"issue":"3","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CND.0b013e31822721ca","article-title":"Exertional rhabdomyolysis: a clinical review with a focus on genetic influences","volume":"13","author":"Landau ME","year":"2012","unstructured":"Landau ME Kenney K Deuster P Campbell W. Exertional rhabdomyolysis: a clinical review with a focus on genetic influences. J Clin Neuromuscul Dis 2012;13(3):122\u2013136. doi:10.1097\/CND.0b013e31822721ca.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0960-8966(02)00008-1","article-title":"A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population","volume":"12","author":"Gross M","year":"2002","unstructured":"Gross M R\u00f6tzer E K\u00f6lle P A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul Disord 2002;12(6):558\u2013565. doi:10.1016\/S0960-8966(02)00008-1.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00421-008-0683-0","article-title":"The effect of AMPD1 genotype on blood flow response to sprint exercise","volume":"103","author":"Norman B","year":"2008","unstructured":"Norman B Nygren AT Nowak J Sabina RL. The effect of AMPD1 genotype on blood flow response to sprint exercise. Eur J Appl Physiol 2008;103(2):173\u2013180. doi:10.1007\/s00421-008-0683-0.","journal-title":"Eur J Appl Physiol"},{"issue":"3","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1469-7793.2001.t01-1-00881.x","article-title":"Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans","volume":"533","author":"Tarnopolsky MA","year":"2001","unstructured":"Tarnopolsky MA Parise G Gibala MJ Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 2001;533(pt 3):881\u2013889. doi:10.1111\/j.1469-7793.2001.t01-1-00881.x.","journal-title":"J Physiol"},{"issue":"4","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mus.24302","article-title":"Novel ANO5 homozygous microdeletion causing myalgia and unprovoked rhabdomyolysis in an Arabic man","volume":"50","author":"Lahoria R","year":"2014","unstructured":"Lahoria R Winder TL Lui J Novel ANO5 homozygous microdeletion causing myalgia and unprovoked rhabdomyolysis in an Arabic man. Muscle Nerve 2014;50(4):610\u2013613. doi:10.1002\/mus.24302.","journal-title":"Muscle Nerve"},{"issue":"6","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mus.21823","article-title":"Pseudometabolic presentation of dystrophinopathy due to a missense mutation","volume":"42","author":"Veerapandiyan A","year":"2010","unstructured":"Veerapandiyan A Shashi V Jiang YH Pseudometabolic presentation of dystrophinopathy due to a missense mutation. Muscle Nerve 2010;42(6):975\u2013979. doi:10.1002\/mus.21823.","journal-title":"Muscle Nerve"},{"issue":"8","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneur.64.8.1176","article-title":"Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes","volume":"64","author":"Nguyen K","year":"2007","unstructured":"Nguyen K Bassez G Krahn M Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007;64(8):1176\u20131182. doi:10.1001\/archneur.64.8.1176.","journal-title":"Arch Neurol"},{"issue":"2","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker BA","year":"2012","unstructured":"Parker BA Augeri AL Capizzi JA Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 2012;109(2):282\u2013287. doi:10.1016\/j.amjcard.2011.08.045.","journal-title":"Am J Cardiol"},{"issue":"12","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/0026-0495(91)90039-Y","article-title":"Effects of exercise and lovastatin on serum creatine kinase activity","volume":"40","author":"Thompson PD","year":"1991","unstructured":"Thompson PD Gadaleta PA Yurgalevitch S Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism 1991;40(12):1333\u20131336. doi:10.1016\/0026-0495(91)90039-Y.","journal-title":"Metabolism"},{"issue":"3","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11536130-000000000-00000","article-title":"The risk for significant creatine kinase elevation with statins","volume":"10","author":"Stolcpart RS","year":"2010","unstructured":"Stolcpart RS Olson KL Delate T The risk for significant creatine kinase elevation with statins. Am J Cardiovasc Drugs 2010;10(3):187\u2013192. doi:10.2165\/11536130-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"13","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson PD","year":"2003","unstructured":"Thompson PD Clarkson P Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681\u20131690. doi:10.1001\/jama.289.13.1681.","journal-title":"JAMA"},{"issue":"5","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1017\/cjn.2014.22","article-title":"Statin-associated autoimmune myopathies: a pathophysiologic spectrum","volume":"41","author":"Wu Y","year":"2014","unstructured":"Wu Y Lach B Provias JP Statin-associated autoimmune myopathies: a pathophysiologic spectrum. Can J Neurol Sci 2014;41(5):638\u2013647. doi:10.1017\/cjn.2014.22.","journal-title":"Can J Neurol Sci"},{"issue":"2","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu GD","year":"2006","unstructured":"Vladutiu GD Simmons Z Isackson PJ Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34(2):153\u2013162. doi:10.1002\/mus.20567.","journal-title":"Muscle Nerve"},{"issue":"3","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mus.10330","article-title":"Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing","volume":"27","author":"Tarnopolsky M","year":"2003","unstructured":"Tarnopolsky M Stevens L MacDonald JR Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing. Muscle Nerve 2003;27(3):359\u2013366. doi:10.1002\/mus.10330.","journal-title":"Muscle Nerve"},{"issue":"3","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/00005768-200003000-00024","article-title":"American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation","volume":"32","author":"Terjung RL","year":"2000","unstructured":"Terjung RL Clarkson P Eichner ER American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000;32(3):706\u2013717. doi:10.1097\/00005768-200003000-00024.","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1469-7793.1997.703bj.x","article-title":"Anaplerotic processes in human skeletal muscle during brief dynamic exercise","volume":"502","author":"Gibala MJ","year":"1997","unstructured":"Gibala MJ MacLean DA Graham TE Saltin B. Anaplerotic processes in human skeletal muscle during brief dynamic exercise. J Physiol 1997;502(pt 3):703\u2013713. doi:10.1111\/j.1469-7793.1997.703bj.x.","journal-title":"J Physiol"},{"issue":"5","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/jappl.2000.88.5.1707","article-title":"Substrate metabolism during different exercise intensities in endurance-trained women","volume":"88","author":"Romijn JA","year":"2000","unstructured":"Romijn JA Coyle EF Sidossis LS Substrate metabolism during different exercise intensities in endurance-trained women. J Appl Physiol (1985) 2000;88(5):1707\u20131714.","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1152\/jappl.1996.81.5.2182","article-title":"Effects of training duration on substrate turnover and oxidation during exercise","volume":"81","author":"Phillips SM","year":"1996","unstructured":"Phillips SM Green HJ Tarnopolsky MA Effects of training duration on substrate turnover and oxidation during exercise. J Appl Physiol (1985) 1996;81(5):2182\u20132191.","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"e_1_3_1_22_2","first-page":"E265","article-title":"Progressive effect of endurance training on metabolic adaptations in working skeletal muscle","volume":"270","author":"Phillips SM","year":"1996","unstructured":"Phillips SM Green HJ Tarnopolsky MA Progressive effect of endurance training on metabolic adaptations in working skeletal muscle. Am J Physiol 1996;270(2 pt 1):E265\u2013E272.","journal-title":"Am J Physiol"},{"issue":"4","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"E580","DOI":"10.1152\/ajpendo.2000.278.4.E580","article-title":"Endurance exercise training attenuates leucine oxidation and BCOAD activation during exercise in humans","volume":"278","author":"McKenzie S","year":"2000","unstructured":"McKenzie S Phillips SM Carter SL Endurance exercise training attenuates leucine oxidation and BCOAD activation during exercise in humans. Am J Physiol Endocrinol Metab 2000;278(4):E580\u2013E587.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"e0126122","DOI":"10.1371\/journal.pone.0126122","article-title":"Activation of AMPK\u03b12 is not required for mitochondrial FAT\/CD36 accumulation during exercise","volume":"10","author":"Monaco C","year":"2015","unstructured":"Monaco C Whitfield J Jain SS Activation of AMPK\u03b12 is not required for mitochondrial FAT\/CD36 accumulation during exercise. PLoS One 2015;10(5):e0126122. doi:10.1371\/journal.pone.0126122.","journal-title":"PLoS One"},{"issue":"1","key":"e_1_3_1_25_2","first-page":"13","article-title":"Myopathy due to a defect in muscle glycogen breakdown","volume":"10","author":"McArdle B","year":"1951","unstructured":"McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 1951;10(1):13\u201335.","journal-title":"Clin Sci"},{"issue":"20","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1212\/01.wnl.0000289190.66955.67","article-title":"Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?","volume":"70","author":"\u00d8rngreen MC","year":"2008","unstructured":"\u00d8rngreen MC Schelhaas HJ Jeppesen TD Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008;70(20):1876\u20131882. doi:10.1212\/01.wnl.0000289190.66955.67.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/WNL.0b013e31824365f9","article-title":"Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease?","volume":"78","author":"Preisler N","year":"2012","unstructured":"Preisler N Orngreen MC Echaniz-Laguna A Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology 2012;78(4):265\u2013268. doi:10.1212\/WNL.0b013e31824365f9.","journal-title":"Neurology"},{"issue":"9","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneur.59.9.1395","article-title":"Spontaneous \u201csecond wind\u201d and glucose-induced second \u201csecond wind\u201d in McArdle disease: oxidative mechanisms","volume":"59","author":"Haller RG","year":"2002","unstructured":"Haller RG Vissing J. Spontaneous \u201csecond wind\u201d and glucose-induced second \u201csecond wind\u201d in McArdle disease: oxidative mechanisms. Arch Neurol 2002;59(9):1395\u20131402. doi:10.1001\/archneur.59.9.1395.","journal-title":"Arch Neurol"},{"issue":"9","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/archneur.62.9.1440","article-title":"Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency","volume":"62","author":"Vissing J","year":"2005","unstructured":"Vissing J Quistorff B Haller RG. Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 2005;62(9):1440\u20131443. doi:10.1001\/archneur.62.9.1440.","journal-title":"Arch Neurol"},{"issue":"1","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.62.1.82","article-title":"No spontaneous second wind in muscle phosphofructokinase deficiency","volume":"62","author":"Haller RG","year":"2004","unstructured":"Haller RG Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 2004;62(1):82\u201386. doi:10.1212\/WNL.62.1.82.","journal-title":"Neurology"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1002\/mus.880181416","article-title":"Myogenic hyperuricemia: what can we learn from metabolic myopathies?","volume":"3","author":"Mineo I","year":"1995","unstructured":"Mineo I Tarui S. Myogenic hyperuricemia: what can we learn from metabolic myopathies? Muscle Nerve Suppl 1995;3:S75\u2013S81. doi:10.1002\/mus.880181416.","journal-title":"Muscle Nerve Suppl"},{"issue":"6","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00415-006-0101-7","article-title":"Lactate production upon short-term non-ischemic forearm exercise in mitochondrial disorders and other myopathies","volume":"253","author":"Hanisch F","year":"2006","unstructured":"Hanisch F Eger K Bork S Lactate production upon short-term non-ischemic forearm exercise in mitochondrial disorders and other myopathies. J Neurol 2006;253(6):735\u2013740. doi:10.1007\/s00415-006-0101-7.","journal-title":"J Neurol"},{"issue":"2","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ana.10263","article-title":"A nonischemic forearm exercise test for McArdle disease","volume":"52","author":"Kazemi-Esfarjani P","year":"2002","unstructured":"Kazemi-Esfarjani P Skomorowska E Jensen TD A nonischemic forearm exercise test for McArdle disease. Ann Neurol 2002;52(2):153\u2013159. doi:10.1002\/ana.10263.","journal-title":"Ann Neurol"},{"issue":"9","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/1097-4598(200009)23:9<1316::AID-MUS2>3.0.CO;2-I","article-title":"Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy","volume":"23","author":"Argov Z","year":"2000","unstructured":"Argov Z L\u00f6fberg M Arnold DL. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 2000;23(9):1316\u20131334. doi:10.1002\/1097-4598(200009)23:9<1316::AID-MUS2>3.0.CO;2-I.","journal-title":"Muscle Nerve"},{"issue":"4","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/JSM.0b013e3180f6168c","article-title":"Favorable responses to acute and chronic exercise in McArdle patients","volume":"17","author":"Mat\u00e9-Mu\u00f1oz JL","year":"2007","unstructured":"Mat\u00e9-Mu\u00f1oz JL Moran M P\u00e9rez M Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 2007;17(4):297\u2013303. doi:10.1097\/JSM.0b013e3180f6168c.","journal-title":"Clin J Sport Med"},{"issue":"12","key":"e_1_3_1_36_2","first-page":"CD007931","article-title":"Physical training for McArdle disease","author":"Quinlivan R","year":"2011","unstructured":"Quinlivan R Vissing J Hilton-Jones D Buckley J. Physical training for McArdle disease. Cochrane Database Syst Rev 2011;(12):CD007931. doi:10.1002\/14651858.CD007931.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ana.20881","article-title":"Aerobic conditioning: an effective therapy in McArdle\u2019s disease","volume":"59","author":"Haller RG","year":"2006","unstructured":"Haller RG Wyrick P Taivassalo T Vissing J. Aerobic conditioning: an effective therapy in McArdle\u2019s disease. Ann Neurol 2006;59(6):922\u2013928. doi:10.1002\/ana.20881.","journal-title":"Ann Neurol"},{"issue":"6","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archneur.65.6.786","article-title":"Effect of oral sucrose shortly before exercise on work capacity in McArdle disease","volume":"65","author":"Andersen ST","year":"2008","unstructured":"Andersen ST Haller RG Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 2008;65(6):786\u2013789. doi:10.1001\/archneur.65.6.786.","journal-title":"Arch Neurol"},{"issue":"26","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa031836","article-title":"The effect of oral sucrose on exercise tolerance in patients with McArdle\u2019s disease","volume":"349","author":"Vissing J","year":"2003","unstructured":"Vissing J Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle\u2019s disease. N Engl J Med 2003;349(26):2503\u20132509. doi:10.1056\/NEJMoa031836.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1056\/NEJM199102073240603","article-title":"Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency","volume":"324","author":"Haller RG","year":"1991","unstructured":"Haller RG Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 1991;324(6):364\u2013369. doi:10.1056\/NEJM199102073240603.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mus.22290","article-title":"Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy","volume":"45","author":"Sato S","year":"2012","unstructured":"Sato S Ohi T Nishino I Sugie H. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve 2012;45(3):436\u2013440. doi:10.1002\/mus.22290.","journal-title":"Muscle Nerve"},{"issue":"15","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2169\/internalmedicine.49.3525","article-title":"A case of McArdle disease: efficacy of vitamin B6 on fatigability and impaired glycogenolysis","volume":"49","author":"Izumi R","year":"2010","unstructured":"Izumi R Suzuki N Kato K A case of McArdle disease: efficacy of vitamin B6 on fatigability and impaired glycogenolysis. Intern Med 2010;49(15):1623\u20131625. doi:10.2169\/internalmedicine.49.3525.","journal-title":"Intern Med"},{"issue":"5","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1212\/WNL.51.5.1456","article-title":"Oral branched-chain amino acids do not improve exercise capacity in McArdle disease","volume":"51","author":"MacLean D","year":"1998","unstructured":"MacLean D Vissing J Vissing SF Haller RG. Oral branched-chain amino acids do not improve exercise capacity in McArdle disease. Neurology 1998;51(5):1456\u20131459. doi:10.1212\/WNL.51.5.1456.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archneur.57.7.956","article-title":"Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial","volume":"57","author":"Vorgerd M","year":"2000","unstructured":"Vorgerd M Grehl T Jager M Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 2000;57(7):956\u2013963. doi:10.1001\/archneur.57.7.956.","journal-title":"Arch Neurol"},{"issue":"17","key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1212\/WNL.0000000000001518","article-title":"Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III","volume":"84","author":"Preisler N","year":"2015","unstructured":"Preisler N Lafor\u00eat P Madsen KL Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. Neurology 2015;84(17):1767\u20131771. doi:10.1212\/WNL.0000000000001518.","journal-title":"Neurology"},{"key":"e_1_3_1_46_2","first-page":"CD003458","article-title":"Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V)","volume":"11","author":"Quinlivan R","year":"2014","unstructured":"Quinlivan R Martinuzzi A Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev 2014;11:CD003458. doi:10.1002\/14651858.CD003458.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"e_1_3_1_47_2","first-page":"64","article-title":"Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor","volume":"26","author":"Martinuzzi A","year":"2007","unstructured":"Martinuzzi A Liava A Trevisi E Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor. Acta Myol 2007;26(1):64\u201366.","journal-title":"Acta Myol"},{"issue":"1","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/bdd.1816","article-title":"Pharmacological and pathophysiological roles of carnitine\/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21)","volume":"34","author":"Tamai I","year":"2013","unstructured":"Tamai I. Pharmacological and pathophysiological roles of carnitine\/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos 2013;34(1):29\u201344. doi:10.1002\/bdd.1816.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.WNL.0000078195.05396.20","article-title":"Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency","volume":"61","author":"\u00d8rngreen MC","year":"2003","unstructured":"\u00d8rngreen MC Ejstrup R Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003;61(4):559\u2013561. doi:10.1212\/01.WNL.0000078195.05396.20.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.59.7.1046","article-title":"Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose","volume":"59","author":"\u00d8rngreen MC","year":"2002","unstructured":"\u00d8rngreen MC Olsen DB Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology 2002;59(7):1046\u20131051. doi:10.1212\/WNL.59.7.1046.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/mgme.1999.2938","article-title":"Carnitine palmitoyltransferase deficiencies","volume":"68","author":"Bonnefont JP","year":"1999","unstructured":"Bonnefont JP Demaugre F Prip-Buus C Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 1999;68(4):424\u2013440. doi:10.1006\/mgme.1999.2938.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajmg.c.30087","article-title":"Disorders of carnitine transport and the carnitine cycle","volume":"142","author":"Longo N","year":"2006","unstructured":"Longo N Amat di San Filippo C Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C(2):77\u201385. doi:10.1002\/ajmg.c.30087.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2010.55","article-title":"Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency","volume":"88","author":"Bonnefont JP","year":"2010","unstructured":"Bonnefont JP Bastin J Lafor\u00eat P Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther 2010;88(1):101\u2013108. doi:10.1038\/clpt.2010.55.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/WNL.0000000000000118","article-title":"Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial","volume":"82","author":"\u00d8rngreen MC","year":"2014","unstructured":"\u00d8rngreen MC Madsen KL Preisler N Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 2014;82(7):607\u2013613. doi:10.1212\/WNL.0000000000000118.","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_1_55_2","first-page":"332","article-title":"Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential","volume":"29","author":"Roe CR","year":"2006","unstructured":"Roe CR Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 2006;29(2\u20133):332\u2013340. doi:10.1007\/s10545-006-0290-3.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.wnl.0000318283.42961.e9","article-title":"Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy","volume":"71","author":"Roe CR","year":"2008","unstructured":"Roe CR Yang BZ Brunengraber H Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008;71(4):260\u2013264. doi:10.1212\/01.wnl.0000318283.42961.e9.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_1_57_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2015.06.006","article-title":"Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment\u2014a retrospective chart review","volume":"116","author":"Vockley J","year":"2015","unstructured":"Vockley J Marsden D McCracken E Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment\u2014a retrospective chart review. Mol Genet Metab 2015;116(1\u20132):53\u201360. doi:10.1016\/j.ymgme.2015.06.006.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.mito.2013.09.003","article-title":"Practice patterns of mitochondrial disease physicians in North America. Part 2: treatment, care and management","volume":"13","author":"Parikh S","year":"2013","unstructured":"Parikh S Goldstein A Koenig MK Practice patterns of mitochondrial disease physicians in North America. Part 2: treatment, care and management. Mitochondrion 2013;13(6):681\u2013687. doi:10.1016\/j.mito.2013.09.003.","journal-title":"Mitochondrion"},{"issue":"9","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/gim.2014.177","article-title":"Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society","volume":"17","author":"Parikh S","year":"2015","unstructured":"Parikh S Goldstein A Koenig MK Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med 2015;17(9):689\u2013701. doi:10.1038\/gim.2014.177.","journal-title":"Genet Med"},{"issue":"13","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.addr.2008.05.001","article-title":"The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies","volume":"60","author":"Tarnopolsky MA","year":"2008","unstructured":"Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev 2008;60(13\u201314):1561\u20131567. doi:10.1016\/j.addr.2008.05.001.","journal-title":"Adv Drug Deliv Rev"},{"issue":"20","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1056\/NEJM198905183202002","article-title":"A mitochondrial DNA mutation as a cause of Leber\u2019s hereditary optic neuropathy","volume":"320","author":"Singh G","year":"1989","unstructured":"Singh G Lott MT Wallace DC. A mitochondrial DNA mutation as a cause of Leber\u2019s hereditary optic neuropathy. N Engl J Med 1989;320(20):1300\u20131305. doi:10.1056\/NEJM198905183202002.","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1212\/WNL.38.5.751","article-title":"MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission","volume":"38","author":"Montagna P","year":"1988","unstructured":"Montagna P Gallassi R Medori R MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988;38(5):751\u2013754. doi:10.1212\/WNL.38.5.751.","journal-title":"Neurology"},{"issue":"6158","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/331717a0","article-title":"Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies","volume":"331","author":"Holt IJ","year":"1988","unstructured":"Holt IJ Harding AE Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331(6158):717\u2013719. doi:10.1038\/331717a0.","journal-title":"Nature"},{"issue":"5655","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1088434","article-title":"Effects of purifying and adaptive selection on regional variation in human mtDNA","volume":"303","author":"Ruiz-Pesini E","year":"2004","unstructured":"Ruiz-Pesini E Mishmar D Brandon M Effects of purifying and adaptive selection on regional variation in human mtDNA. Science 2004;303(5655):223\u2013226. doi:10.1126\/science.1088434.","journal-title":"Science"},{"issue":"12","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C","article-title":"A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies","volume":"20","author":"Tarnopolsky MA","year":"1997","unstructured":"Tarnopolsky MA Roy BD MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20(12):1502\u20131509. doi:10.1002\/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C.","journal-title":"Muscle Nerve"},{"issue":"2","key":"e_1_3_1_66_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbrc.2010.10.060","article-title":"MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation","volume":"402","author":"Connolly BS","year":"2010","unstructured":"Connolly BS Feigenbaum AS Robinson BH MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation. Biochem Biophys Res Commun 2010;402(2):443\u2013447. doi:10.1016\/j.bbrc.2010.10.060.","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"e_1_3_1_67_2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJM199909303411404","article-title":"Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA","volume":"341","author":"Andreu AL","year":"1999","unstructured":"Andreu AL Hanna MG Reichmann H Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med 1999;341(14):1037\u20131044. doi:10.1056\/NEJM199909303411404.","journal-title":"N Engl J Med"},{"issue":"20","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.0b013e3182929fb2","article-title":"Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene","volume":"80","author":"Vissing CR","year":"2013","unstructured":"Vissing CR Duno M Olesen JH Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene. Neurology 2013;80(20):1908\u20131910. doi:10.1212\/WNL.0b013e3182929fb2.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pmr.2011.11.011","article-title":"Exercise testing in metabolic myopathies","volume":"23","author":"Tarnopolsky M","year":"2012","unstructured":"Tarnopolsky M. Exercise testing in metabolic myopathies. Phys Med Rehabil Clin N Am 2012;23(1):173\u2013186, xii. doi:10.1016\/j.pmr.2011.11.011.","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"8","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"e6518","DOI":"10.1371\/journal.pone.0006518","article-title":"Limb immobilization induces a coordinate down-regulation of mitochondrial and other metabolic pathways in men and women","volume":"4","author":"Abadi A","year":"2009","unstructured":"Abadi A Glover EI Isfort RJ Limb immobilization induces a coordinate down-regulation of mitochondrial and other metabolic pathways in men and women. PLoS One 2009;4(8):e6518. doi:10.1371\/journal.pone.0006518.","journal-title":"PLoS One"},{"issue":"10","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1212\/WNL.58.10.1533","article-title":"A forearm exercise screening test for mitochondrial myopathy","volume":"58","author":"Jensen TD","year":"2002","unstructured":"Jensen TD Kazemi-Esfarjani P Skomorowska E Vissing J. A forearm exercise screening test for mitochondrial myopathy. Neurology 2002;58(10):1533\u20131538. doi:10.1212\/WNL.58.10.1533.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.20708","article-title":"Impaired oxygen extraction in metabolic myopathies: detection and quantification by near-infrared spectroscopy","volume":"35","author":"Grassi B","year":"2007","unstructured":"Grassi B Marzorati M Lanfranconi F Impaired oxygen extraction in metabolic myopathies: detection and quantification by near-infrared spectroscopy. Muscle Nerve 2007;35(4):510\u2013520. doi:10.1002\/mus.20708.","journal-title":"Muscle Nerve"},{"issue":"3","key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mrm.1910010303","article-title":"Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR","volume":"1","author":"Arnold DL","year":"1984","unstructured":"Arnold DL Matthews PM Radda GK. Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR. Magn Reson Med 1984;1(3):307\u2013315. doi:10.1002\/mrm.1910010303.","journal-title":"Magn Reson Med"},{"issue":"5","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.mito.2004.07.036","article-title":"Pathology of skeletal muscle in mitochondrial disorders","volume":"4","author":"Bourgeois JM","year":"2004","unstructured":"Bourgeois JM Tarnopolsky MA. Pathology of skeletal muscle in mitochondrial disorders. Mitochondrion 2004;4(5\u20136):441\u2013452. doi:10.1016\/j.mito.2004.07.036.","journal-title":"Mitochondrion"},{"key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-61779-504-6_4","article-title":"Biochemical analyses of the electron transport chain complexes by spectrophotometry","volume":"837","author":"Frazier AE","year":"2012","unstructured":"Frazier AE Thorburn DR. Biochemical analyses of the electron transport chain complexes by spectrophotometry. Methods Mol Biol 2012;837:49\u201362. doi:10.1007\/978-1-61779-504-6_4.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"e_1_3_1_76_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ymgme.2014.11.016","article-title":"Mitochondrial Disease Sequence Data Resource (MSeqDR): a global grass-roots consortium to facilitate deposition, curation, annotation, and integrated analysis of genomic data for the mitochondrial disease clinical and research communities","volume":"114","author":"Falk MJ","year":"2015","unstructured":"Falk MJ Shen L Gonzalez M Mitochondrial Disease Sequence Data Resource (MSeqDR): a global grass-roots consortium to facilitate deposition, curation, annotation, and integrated analysis of genomic data for the mitochondrial disease clinical and research communities. Mol Genet Metab 2015;114(3):388\u2013396. doi:10.1016\/j.ymgme.2014.11.016.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mus.21758","article-title":"A randomized trial of coenzyme Q10 in mitochondrial disorders","volume":"42","author":"Glover EI","year":"2010","unstructured":"Glover EI Martin J Maher A A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42(5):739\u2013748. doi:10.1002\/mus.21758.","journal-title":"Muscle Nerve"},{"issue":"11","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1212\/WNL.55.11.1748","article-title":"A placebo-controlled crossover trial of creatine in mitochondrial diseases","volume":"55","author":"Klopstock T","year":"2000","unstructured":"Klopstock T Querner V Schmidt F A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000;55(11):1748\u20131751. doi:10.1212\/WNL.55.11.1748.","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mus.20688","article-title":"Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders","volume":"35","author":"Rodriguez MC","year":"2007","unstructured":"Rodriguez MC MacDonald JR Mahoney DJ Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235\u2013242. doi:10.1002\/mus.20688.","journal-title":"Muscle Nerve"},{"issue":"5","key":"e_1_3_1_80_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.1028","article-title":"Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders","volume":"49","author":"Tarnopolsky MA","year":"2001","unstructured":"Tarnopolsky MA Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 2001;49(5):561\u2013574. doi:10.1002\/ana.1028.","journal-title":"Ann Neurol"},{"issue":"1","key":"e_1_3_1_81_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/WNO.0b013e318272c643","article-title":"Effects of idebenone on color vision in patients with leber hereditary optic neuropathy","volume":"33","author":"Rudolph G","year":"2013","unstructured":"Rudolph G Dimitriadis K B\u00fcchner B Effects of idebenone on color vision in patients with leber hereditary optic neuropathy. J Neuroophthalmol 2013;33(1):30\u201336. doi:10.1097\/WNO.0b013e318272c643.","journal-title":"J Neuroophthalmol"},{"issue":"9","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock T","year":"2011","unstructured":"Klopstock T Yu-Wai-Man P Dimitriadis K A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy. Brain 2011;134(pt 9):2677\u20132686. doi:10.1093\/brain\/awr170.","journal-title":"Brain"},{"issue":"1","key":"e_1_3_1_83_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2011.10.009","article-title":"Initial experience in the treatment of inherited mitochondrial disease with EPI-743","volume":"105","author":"Enns GM","year":"2012","unstructured":"Enns GM Kinsman SL Perlman SL Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Mol Genet Metab 2012;105(1):91\u2013102. doi:10.1016\/j.ymgme.2011.10.009.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"e_1_3_1_84_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11940-014-0292-7","article-title":"Treatment of mitochondrial disorders","volume":"16","author":"Avula S","year":"2014","unstructured":"Avula S Parikh S Demarest S Treatment of mitochondrial disorders. Curr Treat Options Neurol 2014;16(6):292. doi:10.1007\/s11940-014-0292-7.","journal-title":"Curr Treat Options Neurol"},{"issue":"5","key":"e_1_3_1_85_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1542\/peds.2005-1226","article-title":"Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children","volume":"117","author":"Stacpoole PW","year":"2006","unstructured":"Stacpoole PW Kerr DS Barnes C Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117(5):1519\u20131531. doi:10.1542\/peds.2005-1226.","journal-title":"Pediatrics"},{"issue":"5","key":"e_1_3_1_86_2","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.1542\/peds.2007-2062","article-title":"Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate","volume":"121","author":"Stacpoole PW","year":"2008","unstructured":"Stacpoole PW Gilbert LR Neiberger RE Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 2008;121(5):e1223\u2013e1228. doi:10.1542\/peds.2007-2062.","journal-title":"Pediatrics"},{"issue":"12","key":"e_1_3_1_87_2","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/brain\/awl282","article-title":"Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions","volume":"129","author":"Taivassalo T","year":"2006","unstructured":"Taivassalo T Gardner JL Taylor RW Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 2006;129(pt 12):3391\u20133401. doi:10.1093\/brain\/awl282.","journal-title":"Brain"},{"issue":"12","key":"e_1_3_1_88_2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1249\/01.mss.0000177446.97671.2a","article-title":"Exercise and training in mitochondrial myopathies","volume":"37","author":"Taivassalo T","year":"2005","unstructured":"Taivassalo T Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005;37(12):2094\u20132101. doi:10.1249\/01.mss.0000177446.97671.2a.","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"e_1_3_1_89_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ana.1050","article-title":"Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects","volume":"50","author":"Taivassalo T","year":"2001","unstructured":"Taivassalo T Shoubridge EA Chen J Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001;50(2):133\u2013141. doi:10.1002\/ana.1050.","journal-title":"Ann Neurol"},{"issue":"9","key":"e_1_3_1_90_2","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/0883073814538512","article-title":"Exercise as a therapeutic strategy for primary mitochondrial cytopathies","volume":"29","author":"Tarnopolsky MA","year":"2014","unstructured":"Tarnopolsky MA. Exercise as a therapeutic strategy for primary mitochondrial cytopathies. J Child Neurol 2014;29(9):1225\u20131234. doi:10.1177\/0883073814538512.","journal-title":"J Child Neurol"},{"issue":"11","key":"e_1_3_1_91_2","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1093\/brain\/awn252","article-title":"Resistance training in patients with single, large-scale deletions of mitochondrial DNA","volume":"131","author":"Murphy JL","year":"2008","unstructured":"Murphy JL Blakely EL Schaefer AM Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008;131(pt 11):2832\u20132840. doi:10.1093\/brain\/awn252.","journal-title":"Brain"},{"issue":"6","key":"e_1_3_1_92_2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/hmg\/8.6.1047","article-title":"Gene shifting: a novel therapy for mitochondrial myopathy","volume":"8","author":"Taivassalo T","year":"1999","unstructured":"Taivassalo T Fu K Johns T Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 1999;8(6):1047\u20131052. doi:10.1093\/hmg\/8.6.1047.","journal-title":"Hum Mol Genet"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201612000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:58:00Z","timestamp":1752155880000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1212\/CON.0000000000000403"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000403","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}